C
C.V. Damaraju
Researcher at Janssen Pharmaceutica
Publications - 37
Citations - 1658
C.V. Damaraju is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Warfarin & Atrial fibrillation. The author has an hindex of 14, co-authored 35 publications receiving 1483 citations. Previous affiliations of C.V. Damaraju include Johnson & Johnson.
Papers
More filters
Journal ArticleDOI
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial
TL;DR: Galantamine showed a therapeutic effect on all key areas of cognitive and non-cognitive abilities in this group of dementia patients and was well tolerated.
Journal ArticleDOI
The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.
TL;DR: Cognitive decline over 36 months of continuous galantamine treatment was substantially less than the predicted cognitive decline of untreated patients with mild to moderate dementia, suggesting that galantamines slows the clinical progression of AD.
Journal ArticleDOI
Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus
TL;DR: Canagliflozin treatment decreased serum uric acid in patients with type 2 diabetes mellitus (T2DM), including those with baseline hyperuricaemia, according to post hoc analysis of pooled data.
Journal ArticleDOI
Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.
Carla M. Canuso,Bryan Dirks,Jennifer Carothers,Colette Kosik-Gonzalez,Cynthia A. Bossie,Young Zhu,C.V. Damaraju,Amir H Kalali,Ramy A. Mahmoud +8 more
TL;DR: Compared with quetiapine, paliperidone extended-release improved symptoms earlier and to a greater degree in patients with recently exacerbated schizophrenia requiring hospitalization, with no unexpected tolerability findings.
Journal ArticleDOI
Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation
TL;DR: This matched cohort analysis indicated that rivaroxaban was associated with significantly higher medication persistence and lower discontinuation rates compared to warfarin.